AbbVie Presents Promising Phase 2 Results for Zumilokibart at EADV 2026 as a Late Breaker

AbbVie Unveils Phase 2 Results for Zumilokibart at EADV 2026

AbbVie, a leader in immunology, recently showcased the primary outcomes of its Phase 2 APEX Part B study concerning Zuimlokibart, a promising treatment for moderate to severe atopic dermatitis (AD). These results were revealed as a late-breaker presentation during the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna, which is being held from September 30 to October 3, 2026.

Background on the APEX Part B Study

The APEX Part B study is an ongoing randomized, double-blind, placebo-controlled clinical trial designed to assess various dosing regimens of zumilokibart in adult patients suffering from moderate to severe AD. In this significant trial, a total of 346 participants were randomly assigned to receive either low, mid, high doses of zumilokibart or a placebo over a 16-week induction period.

The primary endpoint was to determine the proportion of patients achieving at least a 75% improvement in their Eczema Area and Severity Index (EASI) scores (EASI-75) by Week 16. Intriguingly, all dose regimens fulfilled this primary endpoint, delivering robust efficacy results.

Key Findings

At the conclusion of the 16-week study, participants receiving all formulations of zumilokibart illustrated substantial enhancements in their EASI scores when compared to the placebo group. These improvements were notably characterized at the mid and high doses as they exhibited superior outcomes across several secondary endpoints. Remarkably, the mid-dose regimen exhibited early efficacy, achieving earlier reductions in skin severity and itchiness, as assessed via the Itch Numeric Rating Scale (I-NRS).

Alongside efficacy, safety profiles were also closely monitored throughout the study duration. The most commonly reported treatment-emergent adverse events included nasopharyngitis and headaches, with occurrences noted at 5% or higher in any group. Other reported events included conjunctivitis, upper respiratory infections, and urinary tract infections.

Expert Commentary

Dr. Kori Wallace, AbbVie's vice president and global head of immunology clinical development, emphasized the necessity of innovative therapies in atopic dermatitis, stating, "Despite significant advances in treatment options, the need for therapies that provide effective disease control remains. The promising results from the APEX Part B study indicate that zumilokibart may fill this gap, providing rapid improvements in skin and itch symptoms."

Further corroborating this potential was Dr. Melinda Gooderham from the SKiN Centre for Dermatology, noting the mid-dose regimen’s improved skin clearance and itch control by Week 16. She highlighted the importance of dosing frequency in selecting long-term therapies, suggesting that zumilokibart’s profile may align well with patients' needs.

Looking Ahead

Due to the favorable outcomes observed in this study, AbbVie has decided to advance the mid-dose regimen into Phase 3 development, pushing the frontier of treatment options for individuals dealing with AD. Zumilokibart, a monoclonal antibody engineered for an extended half-life, specifically targets interleukin-13 (IL-13). This mechanism marks a significant advancement in the treatment landscape, as IL-13 plays a crucial role in the inflammatory processes characteristic of atopic dermatitis.

In conclusion, as we await further insights from ongoing studies and potential regulatory discussions, the promising data from the APEX Part B study position AbbVie and zumilokibart at the forefront of tackling the unmet needs in atopic dermatitis treatment. The pursuit for enhanced therapeutic options continues, aiming for a future where patients can live free from the burdens of their condition.

For additional information regarding the ongoing clinical trials, one can refer to clinicaltrials.gov under identifier NCT07003425.